These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 23023963)

  • 21. Gadobenate dimeglumine-enhanced MR imaging breast vascular maps: association between invasive cancer and ipsilateral increased vascularity.
    Sardanelli F; Iozzelli A; Fausto A; Carriero A; Kirchin MA
    Radiology; 2005 Jun; 235(3):791-7. PubMed ID: 15845796
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Malignant spiculated breast masses: dynamic contrast enhanced MR (DCE-MR) imaging enhancement characteristics and histopathological correlation.
    Gokalp G; Topal U; Yildirim N; Tolunay S
    Eur J Radiol; 2012 Feb; 81(2):203-8. PubMed ID: 21236612
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Normal dynamic MRI enhancement patterns of the upper abdominal organs: gadoxetic acid compared with gadobutrol.
    Kühn JP; Hegenscheid K; Siegmund W; Froehlich CP; Hosten N; Puls R
    AJR Am J Roentgenol; 2009 Nov; 193(5):1318-23. PubMed ID: 19843748
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Brain tumors: full- and half-dose contrast-enhanced MR imaging at 3.0 T compared with 1.5 T--Initial Experience.
    Krautmacher C; Willinek WA; Tschampa HJ; Born M; Träber F; Gieseke J; Textor HJ; Schild HH; Kuhl CK
    Radiology; 2005 Dec; 237(3):1014-9. PubMed ID: 16237142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Quantitative assessment of therapy related effects after breast conserving therapy with dynamic MRI of the breast].
    Wersebe A; Xydeas T; Clauss T; Dietz K; Belka C; Fersis N; Claussen CD; Müller-Schimpfle M
    Rofo; 2001 Dec; 173(12):1109-17. PubMed ID: 11740672
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A combined high temporal and high spatial resolution 3 Tesla MR imaging protocol for the assessment of breast lesions: initial results.
    Pinker K; Grabner G; Bogner W; Gruber S; Szomolanyi P; Trattnig S; Heinz-Peer G; Weber M; Fitzal F; Pluschnig U; Rudas M; Helbich T
    Invest Radiol; 2009 Sep; 44(9):553-8. PubMed ID: 19652611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [MR imaging of the breast before and after neoadjuvant treatment - enhancement characteristics and T 2 signal intensity of breast cancers and breast parenchyma].
    Siegmann KC; Müller KT; Vogel U; Krauss K; Claussen CD
    Rofo; 2010 Jun; 182(6):493-500. PubMed ID: 19953430
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Contrast enhancement of central nervous system lesions: multicenter intraindividual crossover comparative study of two MR contrast agents.
    Maravilla KR; Maldjian JA; Schmalfuss IM; Kuhn MJ; Bowen BC; Wippold FJ; Runge VM; Knopp MV; Kremer S; Wolansky LJ; Anzalone N; Essig M; Gustafsson L
    Radiology; 2006 Aug; 240(2):389-400. PubMed ID: 16801373
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intraindividual in vivo comparison of gadolinium contrast agents for pharmacokinetic analysis using dynamic contrast enhanced magnetic resonance imaging.
    Liang J; Sammet S; Yang X; Jia G; Takayama Y; Knopp MV
    Invest Radiol; 2010 May; 45(5):233-44. PubMed ID: 20351653
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A new contrast in MR mammography by means of chemical exchange saturation transfer (CEST) imaging at 3 Tesla: preliminary results.
    Schmitt B; Zamecnik P; Zaiss M; Rerich E; Schuster L; Bachert P; Schlemmer HP
    Rofo; 2011 Nov; 183(11):1030-6. PubMed ID: 22034086
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Breast neoplasms: T2* susceptibility-contrast, first-pass perfusion MR imaging.
    Kuhl CK; Bieling H; Gieseke J; Ebel T; Mielcarek P; Far F; Folkers P; Elevelt A; Schild HH
    Radiology; 1997 Jan; 202(1):87-95. PubMed ID: 8988196
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dynamic contrast-enhanced magnetic resonance imaging of breast tumors at 3 and 7 T: a comparison.
    Gruber S; Pinker K; Zaric O; Minarikova L; Chmelik M; Baltzer P; Boubela RN; Helbich T; Bogner W; Trattnig S
    Invest Radiol; 2014 May; 49(5):354-62. PubMed ID: 24619208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media: a comparison of gadoxetic acid and gadobenate dimeglumine.
    Filippone A; Blakeborough A; Breuer J; Grazioli L; Gschwend S; Hammerstingl R; Heinz-Peer G; Kittner T; Laghi A; Leen E; Lencioni R; Lucidarme O; Remplik P; Robinson PJ; Ruehm SG; Schaefer F; Stoupis C; Tombach B; Valette PJ; Zech CJ; Huppertz A
    J Magn Reson Imaging; 2010 Feb; 31(2):356-64. PubMed ID: 20099349
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dynamic bilateral contrast-enhanced MR imaging of the breast: trade-off between spatial and temporal resolution.
    Kuhl CK; Schild HH; Morakkabati N
    Radiology; 2005 Sep; 236(3):789-800. PubMed ID: 16118161
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the three-time-point method for diagnosis of breast lesions in contrast-enhanced MR mammography.
    Hauth EA; Stockamp C; Maderwald S; Mühler A; Kimmig R; Jaeger H; Barkhausen J; Forsting M
    Clin Imaging; 2006; 30(3):160-5. PubMed ID: 16632149
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of cerebral perfusion by first-pass, dynamic, contrast-enhanced, steady-state free-precession MR imaging: an animal study.
    Runge VM; Kirsch JE; Wells JW; Woolfolk CE
    AJR Am J Roentgenol; 1993 Mar; 160(3):593-600. PubMed ID: 8430562
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Handling a high relaxivity contrast material for dynamic breast MR imaging using higher thresholds for the initial enhancement.
    Carbonaro LA; Verardi N; Di Leo G; Sardanelli F
    Invest Radiol; 2010 Mar; 45(3):114-20. PubMed ID: 20065856
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Focal malignant hepatic lesions: MR imaging enhanced with gadolinium benzyloxypropionictetra-acetate (BOPTA)--preliminary results of phase II clinical application.
    Caudana R; Morana G; Pirovano GP; Nicoli N; Portuese A; Spinazzi A; Di Rito R; Pistolesi GF
    Radiology; 1996 May; 199(2):513-20. PubMed ID: 8668804
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phyllodes tumor of the breast: correlation between MR findings and histologic grade.
    Yabuuchi H; Soeda H; Matsuo Y; Okafuji T; Eguchi T; Sakai S; Kuroki S; Tokunaga E; Ohno S; Nishiyama K; Hatakenaka M; Honda H
    Radiology; 2006 Dec; 241(3):702-9. PubMed ID: 17032912
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Locally advanced rectal cancer: MR imaging for restaging after neoadjuvant radiation therapy with concomitant chemotherapy. Part II. What are the criteria to predict involved lymph nodes?
    Lahaye MJ; Beets GL; Engelen SM; Kessels AG; de Bruïne AP; Kwee HW; van Engelshoven JM; van de Velde CJ; Beets-Tan RG
    Radiology; 2009 Jul; 252(1):81-91. PubMed ID: 19403848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.